Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99


Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing.

Narayan A, Carriero NJ, Gettinger SN, Kluytenaar J, Kozak KR, Yock TI, Muscato NE, Ugarelli P, Decker RH, Patel AA.

Cancer Res. 2012 Jul 15;72(14):3492-8. doi: 10.1158/0008-5472.CAN-11-4037. Epub 2012 May 10.


Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.

Xia S, Huang CC, Le M, Dittmar R, Du M, Yuan T, Guo Y, Wang Y, Wang X, Tsai S, Suster S, Mackinnon AC, Wang L.

Lung Cancer. 2015 Oct;90(1):78-84. doi: 10.1016/j.lungcan.2015.07.002. Epub 2015 Jul 15.


Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping.

Kim HR, Lee SY, Hyun DS, Lee MK, Lee HK, Choi CM, Yang SH, Kim YC, Lee YC, Kim SY, Jang SH, Lee JC, Lee KY.

J Exp Clin Cancer Res. 2013 Aug 9;32(1):50. doi: 10.1186/1756-9966-32-50.


Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.

Xu S, Lou F, Wu Y, Sun DQ, Zhang JB, Chen W, Ye H, Liu JH, Wei S, Zhao MY, Wu WJ, Su XX, Shi R, Jones L, Huang XF, Chen SY, Chen J.

Cancer Lett. 2016 Jan 28;370(2):324-31. doi: 10.1016/j.canlet.2015.11.005. Epub 2015 Nov 12.


High-fidelity target sequencing of individual molecules identified using barcode sequences: de novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients.

Kukita Y, Matoba R, Uchida J, Hamakawa T, Doki Y, Imamura F, Kato K.

DNA Res. 2015 Aug;22(4):269-77. doi: 10.1093/dnares/dsv010. Epub 2015 Jun 29.


Clinical next-generation sequencing in patients with non-small cell lung cancer.

Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, Nagarajan R, Seibert K, Baggstrom M, Waqar SN, Pfeifer JD, Morgensztern D, Govindan R.

Cancer. 2015 Feb 15;121(4):631-9. doi: 10.1002/cncr.29089. Epub 2014 Oct 24.


Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.

Huang D, Kim DW, Kotsakis A, Deng S, Lira P, Ho SN, Lee NV, Vizcarra P, Cao JQ, Christensen JG, Kim TM, Sun JM, Ahn JS, Ahn MJ, Park K, Mao M.

Genomics. 2013 Sep;102(3):157-62. doi: 10.1016/j.ygeno.2013.02.006. Epub 2013 Feb 20.


Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Lee JC, Lee JE, Kim SY.

Lung Cancer. 2012 Mar;75(3):321-5. doi: 10.1016/j.lungcan.2011.08.005. Epub 2011 Sep 17.


Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer.

Akca H, Demiray A, Yaren A, Bir F, Koseler A, Iwakawa R, Bagci G, Yokota J.

Cancer Genet. 2013 Mar;206(3):73-80. doi: 10.1016/j.cancergen.2013.01.005. Epub 2013 Mar 9.


Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data.

Kukita Y, Uchida J, Oba S, Nishino K, Kumagai T, Taniguchi K, Okuyama T, Imamura F, Kato K.

PLoS One. 2013 Nov 21;8(11):e81468. doi: 10.1371/journal.pone.0081468. eCollection 2013.


Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.

He C, Zheng L, Xu Y, Liu M, Li Y, Xu J.

Clin Chim Acta. 2013 Oct 21;425:119-24. doi: 10.1016/j.cca.2013.07.012. Epub 2013 Jul 23.


A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.

Jelovac D, Beaver JA, Balukrishna S, Wong HY, Toro PV, Cimino-Mathews A, Argani P, Stearns V, Jacobs L, VanDenBerg D, Kessler J, Jeter S, Park BH, Wolff AC.

Hum Pathol. 2014 Apr;45(4):880-3. doi: 10.1016/j.humpath.2013.10.016. Epub 2013 Oct 31.


Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.

Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, Ferrari G, Annessi V, Lasagni D, Carbonelli C, De Franco S, Brini M, Sgarbi G, Lodi R.

Lung Cancer. 2009 Apr;64(1):92-7. doi: 10.1016/j.lungcan.2008.07.012. Epub 2008 Sep 19.


Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.

Yeo CD, Kim JW, Kim KH, Ha JH, Rhee CK, Kim SJ, Kim YK, Park CK, Lee SH, Park MS, Yim HW.

Lung Cancer. 2013 Aug;81(2):207-12. doi: 10.1016/j.lungcan.2013.04.023. Epub 2013 May 29.


Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, Nishio K.

Clin Cancer Res. 2006 Jul 1;12(13):3915-21.


Evaluation of exome sequencing to estimate tumor burden in plasma.

Klevebring D, Neiman M, Sundling S, Eriksson L, Darai Ramqvist E, Celebioglu F, Czene K, Hall P, Egevad L, Grönberg H, Lindberg J.

PLoS One. 2014 Aug 18;9(8):e104417. doi: 10.1371/journal.pone.0104417. eCollection 2014.


A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.

Sarkar FH, Valdivieso M, Borders J, Yao KL, Raval MM, Madan SK, Sreepathi P, Shimoyama R, Steiger Z, Visscher DW, et al.

Diagn Mol Pathol. 1995 Dec;4(4):266-73.


An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.

Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, Shrager JB, Loo BW Jr, Alizadeh AA, Diehn M.

Nat Med. 2014 May;20(5):548-54. doi: 10.1038/nm.3519. Epub 2014 Apr 6.

Items per page

Supplemental Content

Write to the Help Desk